International Journal of Chemical and Biochemical Sciences (ISSN 2226-9614)[/vc_column_text][/vc_column][/vc_row]
VOLUME 26(20) (2024)
Ranolazine New Potential Therapeutic Aspects
Mennatallah M. Bahgat 1, Ashraf Taye2, Esam Omar Kamel3, Abdulhakim Erian Mustafa Wazeery4, Reham A.M. Ellisy5
1Medical Pharmacology Department, Faculty of Medicine, South Vally University, Qena, Egypt.
2Pharmacology and Toxicology Department, Faculty of Pharmacy, South Vally University, Qena, Egypt.
3Histology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
4Internal Medicine Department, Faculty of Medicine, South Vally University, Qena, Egypt.
5Medical Pharmacology Department, Faculty of Medicine, South Vally University, Qena, Egypt.
Abstract
Since Ranolazine approval as an antianginal medication by the US Food and Drug Administration in 2006, it has been administered to specific patient populations with stable angina. Originally, it was thought that ranolazine’s therapeutic actions were due to its inhibition of the metabolism of fatty acids. However, as research progressed, it became clear that ranolazine’s primary advantageous benefits come from its influence on the heart’s late sodium current. Numerous experimental and clinical studies have tested ranolazine either directly or indirectly on heart failure since late-sodium currents have been found to be involved in various heart pathologies such as ischemia, arrhythmias, systolic and diastolic dysfunctions, and all these conditions are associated with heart failure. The inhibition of the underlying mechanisms of cardiac remodeling, such as ion disruptions, oxidative stress, inflammation, apoptosis, fibrosis, metabolic dysregulation, and neurohormonal dysfunction, by ranolazine is reviewed after any kind of severe injury, along with open questions. Ranolazine additional metabolic properties contribute to its efficacy in treating conditions other than coronary artery disease. Our publication will focus on potential therapeutic applications of ranolazine, extending beyond cardiology.
Keywords: Ranolazine, Coronary artery diseases, Angina, Diabetes, Co-morbidities of diabetes.
Full length article – PDF *Corresponding Author, e-mail: givtofallah@gmail.com Doi # https://doi.org/10.62877/12-IJCBS-24-26-20-12